▶ GLP-1 · SUBTOPIC · MECHANISM
GLP-1 Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Engineered single-molecule agonist at GLP-1, GIP, and glucagon receptors. Investigational compound from Eli Lilly under the codename GLP-1 reference.
PHARMACOKINETIC HALF-LIFE
Reported half-life for GLP-1: ~6 days. Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
MECHANISM CATEGORIES
GLP-1 is tagged in 2 mechanism categories on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.
The incretin axis encompasses GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide), gut hormones released in response to nutrient intake that account for roughly 70% of postprandial insulin secretion. Drugs targeting this axis include single GLP-1 agonists (GLP-3), dual GLP-1/GIP agonists (GLP-2), and triple GLP-1/GIP/glucagon agonists (GLP-1). The axis is the largest commercial pharma category of the 2020s and is responsible for the metabolic-medicine revolution underway in obesity, type 2 diabetes, and cardiometabolic disease.
Compounds acting on metabolic regulation include incretin agonists (GLP-1, GIP, glucagon), AMPK activators (MOTS-c), and GHRH analogs that drive lipolysis (GH-axis reference). The shared therapeutic target is metabolic dysfunction underlying obesity, type 2 diabetes, NAFLD, and the broader cardiometabolic syndrome.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Phase 2 NEJM 2023 reported dose-dependent -7.2% to -17.5% LS mean change at 24w (Jastreboff et al., PMID 37366315). High-quality RCT.
Same trial 48-week extension: -8.7% to -24.2% LS mean. n=338.
Glycemic endpoints improved despite GCGR engagement. Phase 3 TRIUMPH data pending.
Phase 2 GI tolerability profile dose-dependent; dose-related heart-rate increases noted. Phase 3 ongoing.
MECHANISM Q+A
▶ What is GLP-1?
GLP-1 (Eli Lilly code GLP-1 reference) is a synthetic peptide engineered as a triple agonist at the GLP-1, GIP, and glucagon receptors. It is an investigational compound · not FDA-approved · currently in the Phase 3 TRIUMPH program.
▶ How does GLP-1 differ from GLP-2?
GLP-2 is a dual GLP-1R + GIPR agonist. GLP-1 adds glucagon-receptor agonism on top, which is the key pharmacological differentiator and the basis for the deeper observed weight reductions in Phase 2.
▶ What is the half-life of GLP-1?
Published pharmacokinetic data indicate a terminal half-life around six days, consistent with once-weekly dosing in trials.
▶ Why does GLP-1 cause more weight loss than GLP-2 in trials?
The hypothesis is that glucagon-receptor agonism adds a thermogenic / increased-energy-expenditure component on top of the GLP-1R/GIPR appetite-and-insulin effects. Mechanism is under active study.
▶ Does GLP-1 affect heart rate?
Phase 2 reported dose-dependent increases in resting heart rate peaking around 24 weeks before declining. This is a class-level signal for incretin agonists at higher doses.
▶ What does triple receptor agonism mean?
GLP-1 engages three receptors simultaneously: GLP-1R, GIPR, and the glucagon receptor (GCGR). Each receptor drives a distinct branch of metabolic and energy-expenditure signaling; the molecule is engineered to balance all three.
▶ GLP-1 vs GLP-3 prescription analog / GLP-3 · what's different?
GLP-3 (GLP-3 prescription analog, GLP-3 prescription analog) is a GLP-1 receptor agonist only. GLP-1 is a triple agonist at GLP-1, GIP and the glucagon receptor. The added GIP arm increases absolute weight loss over GLP-3 at comparable timepoints. The added glucagon arm drives thermogenic / energy-expenditure signaling that GLP-3 does not produce. Published Phase 2 GLP-1 reached -24.2% body weight at 48 weeks vs the published STEP-1 GLP-3 2.4 mg result of -14.9% at 68 weeks.
CITED LITERATURE
- Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-Hormone-Receptor Agonist GLP-1 for Obesity · A Phase 2 Trial. N Engl J Med 2023. PMID 37366315. link
- Eli Lilly and Company. A Study of GLP-1 reference in Participants With Obesity (Phase 2). ClinicalTrials.gov 2021. NCT04881760. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19